CEO of Amgen visited Amgen deCODE in Reykjavik
Bob Bradway with the leadership team of Amgen deCODE genetics. Bob Bradway, CEO of Amgen, visited the facilities of Amgen deCODE genetics (ADG) on Wednesday, March 11. During the visit he learned about the company’s operations, met with executives and...
Genetic Risk Signal in Lupus Identified Through a Distinctive Dataset
In a paper published in Nature Genetics, researchers at Amgen deCODE genetics and collaborators report an important insight into the genetics of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) : a rare variant in the gene IKBKB (encoding the...
Amgen deCODE Genetics Takes Part in Its First Mission Week in Iceland
Last week, Amgen deCODE Genetics (ADG) participated for the first time in Amgen’s Mission Week — an annual initiative where employees around the world pause to reflect on the purpose of their work and the impact it can have on the lives of others. Throughout the week,...
Running with Purpose: deCODE Team Joins Reykjavik Marathon to Make a Difference
On August 23, seventeen employees from deCODE took part in the Reykjavik Marathon, each running in support of various charities through pledge donations. Together, they raised awareness and funds for organizations that make a difference in the lives of people and...
UNIQUE EXPERTISE
Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using our unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.
UNIQUE CAPABILITIES
We operate the most productive human gene discovery engine in the world, employing our discoveries to identify genetic variations associated with human disease.
OUR PUBLICATIONS
We regularly publish our discoveries in major, peer-reviewed journals, enabling others to further validate and expand upon our findings.